Xenon Pharmaceuticals Inc. 近日公布其研发进展，公司计划于2026年第三季度向美国食品药品监督管理局（FDA）正式提交Azetukalner（XEN1101）用于治疗局灶性癫痫发作（Focal Onset Seizures, FOS）的新药申请（NDA）。这一关键里程碑标志着该药物在癫痫治疗领域的开发进入重要阶段。
Azetukalner是一种新型钾通道开放剂，其III期临床研究已展现出显著疗效与良好安全性。若获批上市，该药物有望为全球数百万局灶性癫痫患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.